A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

BACKGROUND: Despite the significant antitumor activity of pembrolizumab in non-small cell lung cancer (NSCLC), clinical benefit has been less frequently observed in patients whose tumors harbor epidermal growth factor receptor (EGFR) mutations compared to EGFR wild-type patients. Our single center e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Lisberg, A, Cummings, A, Goldman, JW, Bornazyan, K, Reese, N, Wang, T, Coluzzi, P, Ledezma, B, Mendenhall, M, Hunt, J, Wolf, B, Jones, B, Madrigal, J, Horton, J, Spiegel, M, Carroll, J, Gukasyan, J, Williams, T, Sauer, L, Wells, C, Hardy, A, Linares, P, Lim, C, Ma, L, Adame, C, Garon, EB
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6063769/
https://ncbi.nlm.nih.gov/pubmed/29874546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.03.035
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados